Breakthrough in mental health treatment: Intra-Cellular’s Caplyta emerges as a beacon of hope for schizophrenia patients

In a significant development for schizophrenia management, Intra-Cellular Therapies has announced impressive outcomes from a late-stage, Phase III clinical trial evaluating Caplyta (lumateperone) for its ... Read More